Caris Life Sciences has collected $168 million in new funding to support the growth of its precision medicine platforms, ...

Learn more about whether Corcept Therapeutics Incorporated or Novartis AG is a better investment based on AAII's A+ Investor ...

The company said the impacted employees primarily comprise commercial field sales teams for Xolair, Tafinlar and Mekinist (Taf+Mek). A company spokesman told NJBIZ that 17 associates work in New ...

The Albanese government has announced an expansion to treatment options under the Pharmaceutical Benefits Scheme (PBS), amid ...

Entresto, approved in heart failure since 2015, has long been one of Novartis’ top growth drivers, bringing home $4.05 billion in U.S. sales in 2024. That said, a key combination patent on the ...

Tafinlar/Mekinist are a blockbuster treatment regimen for BRAF-positive melanoma that added $737 million to Novartis’ coffers in the first half of the year, the third-largest oncology therapy in ...

Pan-RAF kinase inhibitor Ojemda is competing in the US with Novartis' combination regimen of Tafinlar (dabrafenib) and Mekinist (trametinib), which was approved for paediatric patients with BRAF ...

Prime Minister Anthony Albanese has lashed Trump’s tariffs as “not the act of a friend” and said it would have consequences ...

The company announced in December 2024 that it would cut 139 jobs between February and August, primarily affecting commercial field sales teams for Xolair, Tafinlar, and Mekinist, NJBIZ reported.